Clinical Trial Update: A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing QL1207 to Eylea in wet age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• QL1207

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Wet Age-related Macular Degeneration | Phase 3 | Status: COMPLETED